Abstract
The thrombopoiesis-stimulating agents (TSAs) are a novel class of drugs for the treatment of chronic immune thrombocytopenia (ITP). Roimplostim and eltrombopag, the first two TSAs to enter clinical use, received regulatory approval in 2008 and stand poised to change the treatment paradigm in ITP. However, important questions regarding the safety of these agents, particularly with long-term use, remain partially unanswered. The primary objective of this article is to review the reported toxicities associated with the TSAs including rebound thrombocytopenia, thrombosis, hepatotoxicity, formation of neutralizing antibodies, bone marrow fibrosis, hematologic malignancy, cataract formation, and common adverse events. The incidence and severity of these toxicities as well as strategies for monitoring patient safety and pharmacovigilance are discussed.
Keywords: ITP, thrombopoiesis, romiplostim, eltrombopag
Current Drug Safety
Title: Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia
Volume: 5 Issue: 2
Author(s): Adam Cuker, Elaine Y. Chiang and Douglas B. Cines
Affiliation:
Keywords: ITP, thrombopoiesis, romiplostim, eltrombopag
Abstract: The thrombopoiesis-stimulating agents (TSAs) are a novel class of drugs for the treatment of chronic immune thrombocytopenia (ITP). Roimplostim and eltrombopag, the first two TSAs to enter clinical use, received regulatory approval in 2008 and stand poised to change the treatment paradigm in ITP. However, important questions regarding the safety of these agents, particularly with long-term use, remain partially unanswered. The primary objective of this article is to review the reported toxicities associated with the TSAs including rebound thrombocytopenia, thrombosis, hepatotoxicity, formation of neutralizing antibodies, bone marrow fibrosis, hematologic malignancy, cataract formation, and common adverse events. The incidence and severity of these toxicities as well as strategies for monitoring patient safety and pharmacovigilance are discussed.
Export Options
About this article
Cite this article as:
Cuker Adam, Chiang Y. Elaine and Cines B. Douglas, Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia, Current Drug Safety 2010; 5 (2) . https://dx.doi.org/10.2174/157488610790936196
DOI https://dx.doi.org/10.2174/157488610790936196 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Small Molecule Prodrugs for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Editorial (Thematic Issue: New Therapeutic Bearings for Repositioned Drugs)
Current Topics in Medicinal Chemistry Ruthenium Complexes as Anticancer Agents
Current Medicinal Chemistry Heparin Induced Thrombocytopenia: Pathogenetic, Clinical, Diagnostic and Therapeutic Aspects
Cardiovascular & Hematological Disorders-Drug Targets HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets Therapeutic Targeting of Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Histone Deacetylase Inhibitors in Tumor Immunotherapy
Current Medicinal Chemistry Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Topotecan in Second-Line Treatment of Small-Cell Lung Cancer – How it Works in Our Daily Clinical Practice?
Current Drug Safety Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Current Cancer Drug Targets Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?
Current Pharmacogenomics and Personalized Medicine Myelodysplastic/Myeloproliferative Neoplasms
Current Cancer Therapy Reviews Epigenetic Lesions in Malignant Melanoma
Current Pharmaceutical Biotechnology Mesenchymal Stem Cells for Multiple Sclerosis: Does Neural Differentiation Really Matter?
Current Stem Cell Research & Therapy Possible Mechanisms of Lymphoma Development in Sjogren’s Syndrome
Current Immunology Reviews (Discontinued) NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets Obesity and Inflammation: Colorectal Cancer Engines
Current Molecular Pharmacology